Novastra Appoints Jarett Poll as CFO as OAP-101 Moves Toward Global Trials

Why It Matters

The CFO appointment signals Novastra’s intent to transition from early‑stage proof‑of‑concept to large‑scale, capital‑intensive clinical programs. By securing a finance leader with deep ties to both the biotech investment community and pharmaceutical development, the company is better positioned to raise the substantial funds required for global trials, which can exceed $200 million per program. This shift could accelerate the timeline for OAP-101’s entry into pivotal Phase 3 studies, potentially delivering a new class of immune‑reprogramming therapy to patients who currently do not benefit from checkpoint inhibitors. For CFOs across the biotech sector, Novastra’s strategy illustrates how fractional finance leadership can be leveraged to balance cost efficiency with the need for sophisticated capital‑raising expertise. The approach may become a template for other mid‑stage companies seeking to scale quickly while preserving runway for R&D.

Key Takeaways

• Novastra hires Jarett Poll as fractional CFO on May 18, 2026.
• Poll brings experience from Alfasigma, healthcare investment banking, and private capital investing.
• Appointment coincides with positive Phase 1 data for OAP-101 in checkpoint‑refractory melanoma.
• Company aims to raise $150 million in non‑dilutive funding by mid‑2028 for global trial expansion.
• CEO Junling Guo highlights CFO’s role in advancing XIRT immune infrastructure platform.

Pulse Analysis

Novastra’s decision to bring on a fractional CFO rather than a full‑time executive reflects a pragmatic response to the capital‑intensive nature of modern oncology development. Fractional CFOs can deliver high‑level strategic finance capabilities while preserving cash for R&D, a trade‑off that many mid‑stage biotechs are now evaluating. Poll’s blend of business‑development and investment banking experience equips Novastra to navigate a financing environment that increasingly favors milestone‑linked capital and strategic partnerships over pure equity raises.

Historically, biotech firms that secure strong finance leadership early in their clinical trajectory tend to achieve smoother capital transitions, reducing the risk of funding gaps that can stall trial progress. Novastra’s focus on building XIRT as an upstream immune infrastructure positions it uniquely within the crowded checkpoint‑inhibitor space, but also demands substantial resources to validate the platform across multiple tumor types. By aligning its finance function with this scientific ambition, the company can better articulate value propositions to potential partners, potentially unlocking co‑development deals that share risk and accelerate market entry.

Looking ahead, the success of this appointment will be measured by Novastra’s ability to close its next financing round on favorable terms and to keep its trial timelines on track. If Poll can secure the targeted $150 million and forge strategic alliances, Novastra could emerge as a leading player in immune‑reprogramming therapies, setting a precedent for how finance talent can be leveraged to bridge scientific breakthroughs and commercial reality.